Raymond James Financial
CATX icon

Raymond James Financial’s Perspective Therapeutics CATX Stock Holding History

Raymond James Financial’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,730
Closed -$29.5K – 5320
2025
Q4 		$29.5K Buy
+10,730
New +$30.6K ﹤0.01% 5056
2025
Q3 		– Sell
-1,802
Closed -$6.2K – 5250
2025
Q2 		$6.2K Buy
+1,802
New +$4.76K ﹤0.01% 6097

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial's CATX Position: Q1 2026 in Review

Raymond James Financial sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 10,730 shares — an estimated $29.5K sold.

Raymond James Financial first reported a position in CATX in Q2 2025 and held it in 2 quarters. The position peaked at $29.5K in Q4 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Raymond James Financial reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 10,730 Perspective Therapeutics shares in Q1 2026, an estimated $29.5K.
  • Raymond James Financial first reported a position in Perspective Therapeutics in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Perspective Therapeutics position peaked at $29.5K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.